FEXARAMINE
| 中文名称 | FEXARAMINE |
|---|---|
| 中文同义词 | 3-[3-[(环己基羰基)[[4'-(二甲基氨基)[1,1'-联苯]-4-基]甲基]氨基]苯基]-2-丙烯酸甲酯;3-[3-[(环己基羰基)[[4\'-(二甲基氨基)[1,1\'-联苯]-4-基]甲基]氨基]苯基]-2-丙烯酸甲酯, >98%;(E)-3-(3-(N-((4'-(二甲基氨基)-[1,1'-联苯]-4-基)甲基)环己烷甲酰胺基)苯基)丙烯酸甲酯;FEXARAMINE,受体(FXR)激动剂;化合物FEXARAMINE,10 MM DMSO 溶液;费沙拉明 |
| 英文名称 | Fexaramine |
| 英文同义词 | Fexaramine;3-[3-[(Cyclohexylcarbonyl)[[4\'-(dimethylamino)[1,1\'-biphenyl]-4-yl]methyl]amino]phenyl]-2-Propenoic acid methyl ester, >98%;CS-1691;3-[3-[(Cyclohexylcarbonyl)-[[4'-(dimethylamino)-[1,1'-biphenyl]-4-yl]methyl]amino]phenyl]-2-propenoicacidmethylester;2-Propenoic acid, 3-[3-[(cyclohexylcarbonyl)[[4'-(diMethylaMino)[1,1'-biphenyl]-4-yl]Methyl]aMino]phenyl]-, Methyl ester;(E)-methyl 3-(3-(N-((4'-(dimethylamino)biphenyl-4-yl)methyl)cyclohexanecarboxamido)phenyl)acrylate;(2E,4Z)-5-(3-(N-((4'-(dimethylamino)biphenyl-4-yl)methyl)cyclohexanecarboxamido)phenyl)-4-(methoxycarbonyl)penta-2,4-dienoic acid;3-[3-[(Cyclohexylcarbonyl)-[[4'-(dimethylamino)-[1,1'-biphenyl]-4-yl]methyl]amino]phenyl]-2-pr |
| CAS号 | 574013-66-4 |
| 分子式 | C32H36N2O3 |
| 分子量 | 496.64 |
| EINECS号 | |
| 相关类别 | 小分子抑制剂;小分子抑制剂，天然产物;标准品;Inhibitors |
| Mol文件 | 574013-66-4.mol |
| 结构式 |  |
FEXARAMINE 性质
| 沸点 | 677.7±55.0 °C(Predicted) |
|---|---|
| 密度 | 1.158±0.06 g/cm3(Predicted) |
| 储存条件 | 2-8°C |
| 溶解度 | DMSO：50 mg/mL（100.68 mM；需要超声波） |
| 形态 | 粉末 |
| 酸度系数(pKa) | 4.95±0.24(Predicted) |
| 颜色 | 白色至米色 |
| InChIKey | VLQTUNDJHLEFEQ-KGENOOAVSA-N |
| SMILES | C(OC)(=O)/C=C/C1=CC=CC(N(C(C2CCCCC2)=O)CC2=CC=C(C3=CC=C(N(C)C)C=C3)C=C2)=C1 |
Fexaramine是一种有效的、选择性farnesoid X receptor (FXR)激动剂，EC50为25 nM。它对hRXRα, hPPARα, hPPARγ, hPPARδ, mPXR, hPXR, hLXRα, hTRβ, hRARβ, mCAR, mERRγ和hVDR受体没有活性。
| Target | Value |
|
FXR
() | 25 nM(EC50) |
Bile acid treatment is performed in HuTu-80 cells with Fexaramine (5, 25, and 50 μM) for 24 h. Fexaramine (50 μM) increases small heterodimer partner (SHP) transcript levels by 2.1-fold. The cells are treated with various concentrations of Fexaramine, and the endogenous secretin transcript levels are significantly reduced (33% in 50 μM Fexaramine). Fexaramine treatment also significantly suppresses secretin promoter activity by 32%.
Fexaramine treatment of DIO mice produces a striking metabolic profile that includes reduced weight gain, decreased inflammation, browning of WAT and increased insulin sensitization.
安全信息
| WGK Germany | WGK 3 |
|---|---|
| 存储类别 | 11 - 可燃固体 |
| 危险性类别 | 急性毒性 类别4 经口 危害水生环境-长期危害 类别4 |
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026/06/05 | HY-10912R | FEXARAMINE Fexaramine (Standard) | 574013-66-4 | 5 mg | 1875元 |
| 2026/06/05 | HY-10912R | FEXARAMINE Fexaramine (Standard) | 574013-66-4 | 10 mg | 3000元 |